We further show that SLFN11 mRNA level is a tumor biomarker predictive of overall survival (OS) and enhanced tumor response in breast, lung, and ovarian cancer patients treated with these chemotherapeutics. This evidence concerns the gene SLFN11 and ovarian carcinoma.